Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Biesecker Lab/Clinical Genomics Section, |
RCV000172763 | SCV000054830 | benign | not specified | 2013-06-24 | criteria provided, single submitter | research | |
Ambry Genetics | RCV000618223 | SCV000740207 | likely benign | Cardiovascular phenotype | 2017-08-29 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Invitae | RCV001302692 | SCV001491911 | uncertain significance | Hypertrophic cardiomyopathy | 2022-09-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MYH7 protein function. ClinVar contains an entry for this variant (Variation ID: 192191). This variant has not been reported in the literature in individuals affected with MYH7-related conditions. This variant is present in population databases (rs786205356, gnomAD 0.007%). This sequence change replaces arginine, which is basic and polar, with lysine, which is basic and polar, at codon 434 of the MYH7 protein (p.Arg434Lys). |
Cohesion Phenomics | RCV001302692 | SCV003803017 | benign | Hypertrophic cardiomyopathy | 2022-10-10 | no assertion criteria provided | clinical testing |